A Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness And ELEVIDYS Safety Concerns

Recent performance context for Sarepta Therapeutics

Sarepta Therapeutics (SRPT) has drawn investor attention after a period of pressure on the stock, with the share price closing at US$16.80 and posting declines over the past month and past 3 months.

Those moves come against a backdrop of weaker trailing returns over the past year and multi year periods. This has prompted investors to reassess how the company’s current revenue base of US$2.18b and net income of US$65.06m line up with today’s valuation.

See our latest analysis for Sarepta Therapeutics.

Against this backdrop, the stock’s 1 month share price return is down 17.24% and its 1 year total shareholder return is down 56.19%. This points to fading momentum as investors reassess risk and growth expectations.

If this kind of rerating has you rethinking your exposure to high growth healthcare, it could be a good moment to scan other opportunities in AI driven drug development using the 34 healthcare AI stocks.

With Sarepta shares under pressure and the stock trading at a steep discount to one intrinsic estimate, the key question is simple: are you looking at a mispriced rare disease specialist or a market that already expects slower growth?

Most Popular Narrative: 22.4% Undervalued

At a last close of $16.80 against a narrative fair value of $21.65, Sarepta Therapeutics is framed as materially mispriced, with that gap hinging on how its future revenue mix and margins evolve from here.

The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.

Read the complete narrative.

Want to see what drives that valuation gap? The narrative leans heavily on shifting revenue expectations, margin repair and a future earnings multiple well above sector norms. The exact mix of assumptions may surprise you.

Result: Fair Value of $21.65 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the tragic ELEVIDYS safety event, along with any prolonged administrative bottlenecks around gene therapy infusions, could quickly weaken the case for a simple rerating story.

Find out about the key risks to this Sarepta Therapeutics narrative.

Another View: Earnings Multiple Sends A Different Signal

While the narrative fair value points to a 22.4% undervaluation, the simple P/E picture is less generous. Sarepta trades on a P/E of 27.3x, which is above the US Biotechs industry at 16.2x and well above its own fair ratio of 6.7x, even though it is roughly in line with peers at 27.6x.

That gap suggests the market is already paying a high price for each dollar of earnings, with less room for error if profit forecasts or gene therapy uptake fall short. Which signal do you put more weight on: the discounted cash flow style narrative or the earnings multiple?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of pressure on the stock and differing valuation signals leaves you on the fence, it makes sense to move quickly and check the full picture for yourself. Our work highlights both risks and potential upsides that matter for long term holders, starting with 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Sarepta’s story has you thinking more broadly about your portfolio, do not stop here. Use focused stock lists to spot alternatives that better fit your goals.

• Target stability first by checking companies with resilient finances using the 65 resilient stocks with low risk scores.
• Hunt for potential value by reviewing the screener containing 21 high quality undiscovered gems before others catch on.
• Strengthen your core holdings with companies that pair financial resilience and quality in the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com